secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2021-09-20T23:59:59+00:00
Accession:  0001193125-21-276826
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience appoints Brendan Delaney as COO effective Sept 20, 2021
-----------------------------------------------------------------------

- Delaney previously Chief Commercial Officer at Constellation Pharmaceuticals (acquired by MorphoSys for $1.4B) and Immunomedics.
- Annual base salary of $480,000, target bonus of 45%, and option to purchase 260,000 shares vesting over 4 years.
- Severance includes 12 months base salary plus COBRA reimbursement; full acceleration of equity upon change-in-control termination.
- Company highlights upcoming PDUFA date of Nov 26, 2021 for ABI-009 in PEComa and plans to initiate registrational trial for TSC1/TSC2 alterations.
- Delaney will establish Aadi's East Coast presence; has prior roles at Celgene/BMS and Novartis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312521276826/0001193125-21-276826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312521276826/d234049d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-276826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer